Adaptive Biotechnologies (NASDAQ:ADPT) Price Target Raised to $21.00 at JPMorgan Chase & Co.

Adaptive Biotechnologies (NASDAQ:ADPT) had its price objective upped by JPMorgan Chase & Co. from $20.00 to $21.00 in a report issued on Friday morning,Benzinga reports. They currently have an overweight rating on the stock.

Several other analysts also recently commented on the stock. Wall Street Zen downgraded shares of Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a report on Saturday, January 31st. Morgan Stanley started coverage on shares of Adaptive Biotechnologies in a research report on Monday, December 1st. They issued an “equal weight” rating and a $21.00 price objective for the company. Piper Sandler set a $21.00 target price on shares of Adaptive Biotechnologies in a research report on Friday. TD Cowen restated a “buy” rating on shares of Adaptive Biotechnologies in a research note on Friday. Finally, BTIG Research increased their price target on Adaptive Biotechnologies from $21.00 to $22.00 and gave the company a “buy” rating in a research report on Friday. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $17.56.

Adaptive Biotechnologies Stock Down 4.3%

ADPT stock opened at $15.77 on Friday. The firm has a market capitalization of $2.41 billion, a PE ratio of -39.42 and a beta of 2.18. Adaptive Biotechnologies has a twelve month low of $6.26 and a twelve month high of $20.76. The stock’s 50 day moving average is $17.03 and its 200-day moving average is $15.20.

Adaptive Biotechnologies (NASDAQ:ADPT) last announced its quarterly earnings results on Thursday, February 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.10. Adaptive Biotechnologies had a negative return on equity of 48.73% and a negative net margin of 21.48%.The business had revenue of $71.68 million during the quarter, compared to the consensus estimate of $59.38 million. During the same quarter in the prior year, the company posted ($0.23) earnings per share. Adaptive Biotechnologies’s revenue was up 51.0% compared to the same quarter last year. On average, equities research analysts anticipate that Adaptive Biotechnologies will post -0.92 earnings per share for the current fiscal year.

Insider Activity at Adaptive Biotechnologies

In other Adaptive Biotechnologies news, insider Harlan S. Robins sold 8,120 shares of the firm’s stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $19.00, for a total value of $154,280.00. Following the completion of the sale, the insider directly owned 1,179,524 shares of the company’s stock, valued at $22,410,956. This trade represents a 0.68% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Chad M. Robins sold 124,998 shares of the business’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $18.44, for a total value of $2,304,963.12. Following the completion of the sale, the chief executive officer owned 2,459,245 shares in the company, valued at approximately $45,348,477.80. The trade was a 4.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 1,612,461 shares of company stock worth $27,754,413. 6.40% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Adaptive Biotechnologies

Institutional investors have recently made changes to their positions in the stock. Ameriprise Financial Inc. raised its holdings in shares of Adaptive Biotechnologies by 84.3% in the 3rd quarter. Ameriprise Financial Inc. now owns 5,971,706 shares of the company’s stock valued at $89,337,000 after acquiring an additional 2,731,648 shares in the last quarter. Arrowstreet Capital Limited Partnership increased its position in shares of Adaptive Biotechnologies by 544.0% in the third quarter. Arrowstreet Capital Limited Partnership now owns 2,441,402 shares of the company’s stock worth $36,523,000 after purchasing an additional 2,062,282 shares during the last quarter. Jennison Associates LLC increased its position in shares of Adaptive Biotechnologies by 103.9% in the fourth quarter. Jennison Associates LLC now owns 2,674,668 shares of the company’s stock worth $43,437,000 after purchasing an additional 1,363,181 shares during the last quarter. Summit Partners Public Asset Management LLC purchased a new stake in Adaptive Biotechnologies in the third quarter valued at approximately $14,934,000. Finally, First Trust Advisors LP lifted its position in Adaptive Biotechnologies by 4,802.2% during the second quarter. First Trust Advisors LP now owns 741,306 shares of the company’s stock valued at $8,636,000 after purchasing an additional 726,184 shares during the last quarter. Hedge funds and other institutional investors own 99.17% of the company’s stock.

Key Stories Impacting Adaptive Biotechnologies

Here are the key news stories impacting Adaptive Biotechnologies this week:

• Positive Sentiment: Q4 results beat expectations — ADPT reported a $0.09 loss per share vs. a $0.19 consensus loss and revenue of $71.7M (up 51% YoY), which investors typically view as positive for growth outlook. Read More.
• Positive Sentiment: Analyst upgrade/target increase — JPMorgan raised its price target to $21 and maintained an overweight stance, implying meaningful upside versus recent levels and likely supporting buying interest. Read More.
• Neutral Sentiment: Multiple analyst write-ups and coverage: Zacks and other outlets published detail and comparisons to estimates; consensus remains a “Moderate Buy” with an average price target near the mid‑teens to low‑$20s — useful context but not a single catalyst. Read More.
• Neutral Sentiment: Full earnings materials and transcript are available for deeper review (management commentary and slide deck will guide whether revenue quality and guidance justify the rally). Read More.
• Negative Sentiment: Significant insider selling disclosed this week — CEO Chad M. Robins and other insiders sold large blocks (CEO ~125k shares; other insider sales also reported). Large insider sales can pressure sentiment even when results are strong. Read More.
• Negative Sentiment: Company remains unprofitable with negative margins and a negative ROE; analysts still expect a full-year loss (consensus EPS negative), which leaves valuation and timing of profitability as ongoing investor concerns. Read More.
• Neutral Sentiment: Reported short-interest data in this batch is effectively zero/unchanged and shows no immediate short‑squeeze dynamics; days‑to‑cover computed as 0.0, so short interest is not a current market driver. (Item flagged in recent data feeds.)

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.